The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index; 20 of the 98 sources its claims cite were checked for support.
Long-term neurological consequences following benzodiazepine exposure: A scoping review
Open accessAbstract
Benzodiazepine acute withdrawal syndrome is well known, but the long-term neurological consequences of benzodiazepine exposure are much less familiar. A scoping review was conducted of electronic databases for studies that reported on patient outcomes four or more weeks after complete cessation of benzodiazepine use. Forty-six results were retrieved in total, some of which provided signals for protracted symptoms, often reported as incidental findings, and others that showed benzodiazepine discontinuation was beneficial. Some overlap occurred in the outcomes, but these two groups of studies suggest that the benefits of benzodiazepine discontinuation for many patients tended to obscure the more prolonged, severe, and sometimes debilitating symptoms that persisted for months and years in a subpopulation of patients. The prevalence or trajectory of these enduring symptoms could not be determined from these studies. Further elucidation of the potential neurotoxicity of benzodiazepines is needed to better understand protracted symptoms and their treatment. Clinicians, patients, and the healthcare system must be cognizant of the risks of benzodiazepine exposure beyond two to four weeks.
Overview
CoChat Summary
TL;DR
This scoping review of 46 studies found signals that a subpopulation of patients experiences protracted neurological symptoms persisting four or more weeks after benzodiazepine cessation, while many studies showed discontinuation was beneficial. The prevalence and trajectory of enduring symptoms could not be determined, and the authors call for further research into possible benzodiazepine neurotoxicity.
Key findings
- The search retrieved 14,097 publications and included 46 studies; the Results section reports that 28 of 46 (61%) provided signals of a protracted withdrawal phase, while the Discussion states 27 provided such signals.
- Acute withdrawal occurred in up to 100% of participants in some included studies, whereas prolonged symptoms were reported in approximately 30% of benzodiazepine patients; no incidence or prevalence data were found.
- Fourteen studies (30.4%) had as their main finding that benzodiazepine discontinuation was unproblematic and beneficial, but severe protracted symptoms were also reported, including one study where 100% of 20 benzodiazepine patients had neurologic symptoms at six months after complete cessation and another where 28% required antidepressant therapy at 12 weeks after discontinuation.
- No clear risk or protective factors for protracted symptoms were identified, and no randomized clinical trials were designed with enduring symptoms after complete benzodiazepine cessation as an endpoint.
Methods
- Scoping review following JBI evidence synthesis methodology and PRISMA-ScR guidelines; searches were run in August 2023 and updated in December 2024 across Ovid MEDLINE(R) ALL (1946 to December 6, 2024), Embase, and APA PsycInfo.
- Inclusion criteria were adults ≥18 years who used benzodiazepines for >2 weeks and discontinued for >4 weeks, excluding primary psychotic illness or bipolar disorder; experimental studies, observational studies, case studies/series, and clinical trials were included, while clinical trial registrations, commentaries, editorials, correspondence, reviews, conference abstracts, animal studies, grey literature, and non-English/non-peer-reviewed articles were excluded.
- A descriptive analysis of extracted data was performed to identify article type and summarize relevant data for signals of benzodiazepine-induced neurological dysfunction (BIND).
Limitations
- The paper states that no randomized clinical trials were specifically designed to look for enduring symptoms following complete benzodiazepine cessation, so protracted symptoms observed were signals or incidental findings rather than primary endpoints; prevalence and trajectory could not be determined.
- The paper states that the scoping review allowed a broad range of studies of variable quality, that terminology in the literature was inconsistent, and that grey literature and clinical trial registrations were excluded.
- Evident from the text: the Results and Discussion report different counts of studies providing signals (28 vs. 27), and the included literature was mostly published before 1996 with comparatively few results after 2006.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 PRISMA flow diagram adapted from Covidence review software. [27] At the end of the screening, 46 articles were considered.](https://figures.cochat.ai/paper-figures/a55add5948ef46978fb161aceb3dd5f8/long-term-neurological-consequences-following-benzodiazepine-exposure-a-scoping-figure-1.jpg)


Verification
Claims the paper makes
16 Valid · 2 Not valid · 40 Not checked · 52 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Consistent with other published studies and clinical observations, this scoping review showed that some people can discontinue benzodiazepines even after prolonged exposure with relatively little problem [12,13,23].”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Discussion
What the sources say
- Partly supportedcites [12] A Finlayson, 2022, Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey, Ther Adv Psychopharmacol sourceExperimental — accuracy not yet measured
The Symptoms section reports that 5.2% of respondents who discontinued benzodiazepines said they “withdrew just fine without taper,” and Patient comments include a respondent who reported stopping with no withdrawal problems. Neither passage establishes that those particular respondents had prolonged exposure, so the source supports the possibility of relatively easy discontinuation but not that qualifier. (LLM, conf=0.84)
- Partly supportedcites [13] AD Ritvo, 2023, Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey, PLoS One sourceExperimental — accuracy not yet measured
The Results report that 63.2% of survey respondents had completely discontinued benzodiazepines. But the Results and Discussion focus on persistent symptoms and adverse consequences; they do not establish that any respondents discontinued after prolonged exposure with relatively little problem. (LLM, conf=0.81)
- Partly supportedcites [23] C Huff, 2022, Enduring neurological sequelae of benzodiazepine use: an Internet survey, Ther Adv Psychopharmacol sourceExperimental — accuracy not yet measured
The Discussion (page not available in our copy) says protracted symptoms do not occur in all benzodiazepine patients and that use often extends for months or years. It does not establish that people with prolonged exposure can discontinue with relatively little problem; absence of protracted symptoms does not rule out other withdrawal difficulties. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A more prolonged condition had been observed decades ago, which typically can be identified after the acute withdrawal syndrome had abated, although nomenclature was inconsistent [23].”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Background
What the sources say
- Supportedcites [23] C Huff, 2022, Enduring neurological sequelae of benzodiazepine use: an Internet survey, Ther Adv Psychopharmacol source
The Introduction describes prolonged benzodiazepine symptoms reported decades ago, including a 1990 account. The Discussion distinguishes acute withdrawal, lasting roughly 10–28 days, from symptoms persisting for months or years, and says the enduring condition historically had several confusing names. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Reports emerged of prolonged problematic clinical symptoms that could persist after completion of the acute withdrawal syndrome, enduring for months or even years after benzodiazepine cessation [12].”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Background
What the sources say
- Supportedcites [12] A Finlayson, 2022, Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey, Ther Adv Psychopharmacol source
The Introduction distinguishes acute withdrawal from possible longer-term consequences after benzodiazepine cessation. The Discussion/conclusion reports that severe symptoms persisted beyond the short-term withdrawal period, sometimes for months or years after discontinuation. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Many respondents stated they had multiple symptoms, with over 40% reporting more than 17 symptoms lasting for over a year.”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Background
What the sources say
- Partly supportedcites [13] AD Ritvo, 2023, Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey, PLoS One sourceExperimental — accuracy not yet measured
The Discussion reports that over 40% of respondents had at least 17 symptoms lasting at least one year after discontinuation. The claim changes both thresholds: “more than 17” excludes respondents with exactly 17 symptoms, and “over a year” excludes symptoms lasting exactly one year. The paper does not give the percentage meeting those stricter thresholds. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The majority of respondents also reported adverse life consequences, such as the loss of home or business or failed relationships [13].”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Background
What the sources say
- Supportedcites [13] AD Ritvo, 2023, Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey, PLoS One source
The Results report that over 90% of respondents attributed at least one general adverse life consequence to benzodiazepine use. Table 3 lists significantly affected relationships, loss of a home, and loss of a business as specific consequences. The majority figure applies to adverse consequences overall, not to each example individually. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
54 more claims · 4 with their cited sources checked
Create a free account to see all 110 claims and to verify the 4 references still open.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results > A protracted withdrawal phase
“Twenty-eight of the 46 studies retrieved in the scoping review (61%) provide signals that suggest a protracted withdrawal phase.”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Discussion
“This scoping review found 46 studies of benzodiazepine cessation, of which 27 provided signals that certain symptoms persisted or emerged more than four weeks after complete benzodiazepine withdrawal.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results > A protracted withdrawal phase
“Higgitt and colleagues matched nine protracted withdrawal syndrome (PWS) patients to nine anxiety patients not taking any drugs, 13 conversion hysteria patients, and nine healthy controls.”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results
“9 prior BZD users with PWS with 3 matched groups:9 conversion disorder pt9 anxiety disorder pt9 healthy volunteers”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results
“31 BZD users participating in 20 wk taper with counseling to d/c”
§ Long-term neurological consequences following benzodiazepine exposure: A scoping review > Results
“12/33 pt succeeded with d/c.”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0850 · Cited by 43,565 · cited 1×
“The scoping review was conducted following JBI evidence synthesis methodology and the PRISMA ScR guidelines [25,26].”
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Best practice guidance and reporting items for the development of scoping review protocols
Peters, M. D. J., Godfrey, C., McInerney, P., Khalil, H., Larsen, P., Marnie, C., Pollock, D., Tricco, A. C., & Munn, Z. (2022) · JBI Evidence Synthesis · doi:10.11124/jbies-21-00242 · Cited by 1,444
Guidelines for the Rational Use of Benzodiazepines: When and What to Use
Ashton, H. (1994) · Drugs · doi:10.2165/00003495-199448010-00004 · Cited by 593 · cited 1×
“Even short-term use of benzodiazepines may be problematic, because physiologic dependence on benzodiazepines can occur after two to four weeks of use [84–89].”
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573 · cited 1×
“The acute withdrawal syndrome following cessation of chronic benzodiazepine exposure has been well described [19–21].”
Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552 · cited 1×
“Meta-analyses of cognitive effects following withdrawal reported problems with recent memory, processing speed, visuo-construction, divided attention, working memory, and sustained attention [17,18].”
Principles of pharmacology : the pathophysiologic basis of drug therapy
Golan, D. E., & Tashjian, A. H. (2012) · Cited by 469
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 2×
“The incidence of acute withdrawal is dose-and duration-dependent, ranging from approximately 30% to 100% [22].”
Research works printed but not linked: 5
- D Foster, 2018, Benzo Free: The World of Anti-Anxiety Drugs and the Reality of Withdrawal, 309
- Shade K, Ritvo A, Silvernail B, Martin P, Foster D, Huff C, et al. Benzodiazepine induced neurological dysfunction: an overview of adverse long-term neurological consequences following chronic use of benzodiazepines: a scoping review protocol. 2023. · DOI · Paper page
- P Peperkamp, 1993, The discontinuation of lorazepam and diazepam following sub-chronic therapy in anxious outpatients, J Drug Dev, 6, 171
- P Martin, 2017, Pharmacology of drugs of abuse., 308
- HC Rosenberg, 1985, Time course for development of benzodiazepine tolerance and physical dependence, Neurosci Biobehav Rev, 9, 123, 10.1016/0149-7634(85)90038-7 · DOI · Paper page
Cited by
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
“…Dysfunction ’ (BIND) as more appropriate, recognizing that such protracted symptoms often do not respond to re-instatement (Ritvo et al., 2023; Shade et al., 2025), like similar post-cessation-induced neurological dysfunction seen from other classes of psychiatric drugs (Horowitz &…”
Self-citationAyala, J. R. S., Armas, D. A., García, V. H., Aguirre‐Jaime, A., Gutiérrez, A. J., Paz, S., de la Torre, A. H., & Rubio, C. (2025) · Pharmacy · doi:10.3390/pharmacy13060181 · Cited by 1
“Given that abrupt withdrawal can cause rebound symptoms [44], structured withdrawal with monitoring is necessary [3].”
Toward clarifying ASAM’s inpatient and residential benzodiazepine tapering recommendations
Blazes, C. K., Leung, S., Chervin, D. D., & Silvernail, B. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1857354
Self-citationLeistungssteigernde Mittel im Alltag und im Arbeitsleben
Milin, S., Ebel, F. A., & Schäfer, I. (2026) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-026-04254-2
“…darunter Rebound-Effekte (verstärkte Rückkehr der Symptome, die Anlass für den Gebrauch der Substanz waren, nach Abklingen der Wirkung), gesundheitliche Folgen von Mischkonsum sowie Abhängigkeits-und Toleranzentwicklung, insbesondere bei wiederholtem Gebrauch ohne me-dizinische Begleitung [34–36].”
Chakraborty, W., Anand, A., & Roy, K. K. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111846
Metadata
- Authors
- Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R.
- Affiliations
- University of Colorado Anschutz (US)
- Vanderbilt University Medical Center (US)
- Yale University (US)
- Corresponding author
- Shade, Kyla N.
- Ritvo, Alexis D.
- Silvernail, Bernard
- Finlayson, A. J. Reid
- Bressi, Jolene E.
- Foster, D. E.
- Martin, Ian J.
- Piper, Christi
- Martin, Peter R.
- ORCID
- Venue
- PLOS One
- Publisher
- Public Library of Science (PLoS)
- Published
- 2025-08-28
- Volume
- 20
- Issue
- 8
- Pages
- e0330277
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC12393751
- OpenAlex
- W4413786647
- Cited by
- 7
- References
- 88
- Citations by year
- 2026: 6 · 2025: 1
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepines, benzodiazepine withdrawal, benzodiazepine discontinuation, neurotoxicity, benzodiazepine dependence
- MeSH terms
- Benzodiazepines, Humans, Nervous System Diseases, Substance Withdrawal Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term neurological consequences following benzodiazepine exposure: A scoping review. https://app.cochat.ai/papers/10.1371/journal.pone.0330277
- The paper
- Shade, K. N., Ritvo, A. D., Silvernail, B., Finlayson, A. J. R., Bressi, J. E., Foster, D. E., Martin, I. J., Piper, C., & Martin, P. R. (2025). Long-term neurological consequences following benzodiazepine exposure: A scoping review. PLOS One. https://doi.org/10.1371/journal.pone.0330277
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.